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Clinical and cost-effectiveness  
of absorbent dressings in the 
treatment of highly exuding VLUs
l objective: To estimate the clinical effectiveness and cost effectiveness of using a sodium 
carboxymethylcellulose dressing (cMc [aquacel]) and four superabsorbent dressings (DryMax Extra 
[DM], Flivasorb [F], Kerramax [K] and sachet S [S]) in the treatment of highly exuding chronic venous leg 
ulcers (vlUs) in the UK, from the perspective of the national health Service (nhS).
l Method: a decision model was constructed depicting the patient pathways and associated management 
of a cohort of 439 patients with highly exuding chronic vlUs of ≥ 3 months of age. The model was based on 
the case records of a cohort of matched patients from The health Improvement network (ThIn) 
database (a nationally representative database of patients registered with general practitioners (GPs) in the 
UK) who were treated with one of the five dressings. The model estimated the costs and outcomes of 
patient management over 6 months and the relative cost-effectiveness of using each dressing.
l results: Patients’ mean age was 73.1 years, and 46% were female. Between 39% and 56% of vlUs 
healed by 6 months. cMc-treated wounds that remained unhealed increased in size by 43% over the 
study period, whereas unhealed wounds treated with the other dressings decreased in size by a mean 
34%. consequently, cMc was excluded from the cost-effectiveness analysis. The 6-monthly nhS cost of 
managing a vlU with S was £3700 per patient, which was 15–28% lower than the cost of managing 
patients with the other three superabsorbents. additonally, use of S improved patients’ health status to a 
greater extent than the other three superabsorbents, since S-treated patients accrued 0.3–3% more 
QalYs. Starting treatment with S was the preferred strategy followed by DM, K and F in that order.
l conclusion: Within the limitations of the data set, S affords the nhS a cost-effective treatment for 
managing highly exuding chronic vlUs of ≥3 months of age, compared with DM, F, K and cMc.
l declaration of interest: This study was funded with an unrestricted research grant from Sorbion 
Gmbh & co. KG, Senden, Germany, manufacturers of sachet S. however, Sorbion did not have any 
control of the methodology, conduct, results or conclusion of this study, or editorial involvement in this 
manuscript. The authors have no other conflicts of interest that are directly relevant to the content of 
this manuscript, which remains their sole responsibility
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xudate is fluid that filters from the circu-
latory system as a result of inflammatory 
processes, and in acute wounds main-
tains a moist environment and pro-
motes healing.1 In chronic wounds, exu-
date contains a high level of proteases, which can 
be a significant factor in delaying wound healing.2 
A low level of exudate can result in wound dessica-
tion and this can inhibit the healing process.3 
However, an unmanaged high level of exudate can 
cause peri-wound skin damage,4 and may be harm-
ful to the wound bed itself. The optimal level of 
exudate necessary for healthy uncomplicated 
wound healing is unknown.5
Exudate becomes a problem when a dressing leaks, 
a high frequency of dressing change is required, there 
are peri-wound changes, such as maceration or skin 
stripping, patients experience discomfort or pain, 
or there is fluid and electrolyte imbalance owing to 
protein loss.2 Effective exudate management using 
an appropriate dressing is critical.
Successful wound management requires a flexible 
approach to the selection and use of dressings, based 
on an understanding of the healing process and 
knowledge of the properties of the various dressings 
available.2 Many factors influence dressing selection, 
but it should be based upon holistic assessment, 
including physical examination of the patient, past 
medical history and wound history.6 Superabsorbent 
dressings have been designed to manage moderate to 
highly exuding wounds. The dressings contain the 
superabsorbent particle sodium polyacrylate, with 
high absorbency. In the UK, several superabsorbents 
are available on the market, including:
l DryMax Extra (DM; Absorbest AB)
l KerraMax (K; Crawford Healthcare Ltd.)
l Flivasorb (F; Lohmann & Raushcer GmbH & Co.)
l sachet S (S; Sorbion GmbH & Co. KG).
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l Sodium carboxymethylcellulose (CMC [Aquacel]; 
Convatec Inc.) is not a superabsorbent, but is 
used extensively to treat highly exuding wounds 
in the UK.
Therefore, the objective of this study was to esti-
mate the relative clinical and cost-effectiveness of 
using DM, K, F, S and CMC in the treatment of high-
ly exuding chronic venous leg ulcers (VLUs) in the 
UK, from the perspective of the NHS.
Method
The Health Improvement Network (THIN) database 
contains computerised information on more than 
9 million anonymised patients, entered by general 
practitioners (GPs), from 500  practices across the 
UK.7 General practices across the UK using Vision 
Practice Management Software are invited to par-
ticipate in the database, and are self-selecting. The 
data within THIN has been shown to be representa-
tive of the UK population, in terms of demographics 
and disease distribution.8,9
The computerised information in the THIN data-
base includes patients’ demographics, details from 
GP consultations, specialist referrals, nurse and other 
clinician visits, hospital admissions, diagnostic and 
therapeutic procedures, laboratory tests and prescrip-
tions issued by GPs, which are directly generated by 
the general practice’s IT system. Hence, the informa-
tion contained in the THIN database reflects real 
clinical practice, as it is based on actual patient 
records. Moreover, GPs are the gatekeepers to health 
care in the UK, and patients’ entire medical history is 
theoretically stored in their primary care record.
Specific diagnoses are recorded using Read codes. 
Read codes are a coded thesaurus of clinical terms 
that are used by clinicians in the UK to record 
patient findings and procedures in health and social 
care IT systems;10 they have been in use in the NHS 
since 1985.10 A drug dictionary based on data from 
the Multilex classification has been used to code 
drugs in the database.7 Successive updates of 
patients’ records to the database include any subse-
quent changes made by GPs.
The study population comprised a randomised 
sample of 100  matched patients from the THIN 
database, who were treated with either CMC, DM, F, 
K or S, during 2011. Patients were included in the 
study, provided they met the following criteria:
l ≥ 18 years of age.
l VLU duration ≥ 3  months, before receiving their 
first treatment with one of the study dressings
l Not received treatment for their VLU with any of 
this study’s comparators within 6 months of start-
ing treatment with one of the study dressings
l Had at least 6 months’ follow-up data in their case 
record, following the start of treatment.
Patients in each group were matched according to 
age, gender, their general practice, date of diagnosis 
of their VLU and treatment start date. One patient 
in each of the CMC, F, K and S group had to be 
excluded, as they did not meet the inclusion crite-
ria, generating a final sample size of 99 patients per 
group. Fifty-seven patients in the DM group had to 
be excluded because of underlying skin cancer, gen-
erating a final sample size of 43 patients.
ethics approval 
Ethics approval to use patients’ records from the 
THIN database for this study was obtained from a 
Research Ethics Committee that appraises studies 
using the THIN database.
Study variables 
Information extracted from patients’ records includ-
ed age, gender, symptoms, comorbidities and dura-
tion of symptoms. Community-based and second-
ary care VLU-related resource use, over a period of 
6  months following the treatment start date, was 
also extracted. Specific wound size estimates for all 
patients were not available for every dressing 
change. In those instances, and based on previous 
experience,11 patients’ wound size was assumed to 
be 80% of the size of the primary dressing.
Patients’ outcomes and resource use were quanti-
fied for all five groups. Differences between groups 
were tested for statistical significance using a Mann–
Whitney U test or Chi-squared test. Logistic regres-
sion was performed to identify independent predic-
tors of healing. Multiple, ordinary least-squares 
regression was also performed to assess the impact 
of the wounds’ baseline characteristics on resource 
use and clinical outcomes.
Health economic modelling 
A decision model was constructed depicting the 
patient pathways and associated management of 
the cohort of patients in each of the five groups, 
using patient level data. The model was populated 
with probabilities, health-care resource utilisation 
and clinical outcomes extracted from the THIN data 
set. The model spans a period of 6 months following 
the start of treatment with each dressing and com-
prises the following health states: unchanged ulcer, 
improved ulcer, worsened ulcer, healed ulcer and 
death. It was decided that since the time frame was 
relatively short and recurring events (in terms of 
patients moving into different health states) were 
relatively static, a decision model was the most 
appropriate type to address the study objectives.
Utility scores express patient preferences for spe-
cific health states on a scale ranging from 0 (repre-
senting death) to 1 (representing perfect health). 
These scores provide the weights to estimate health-
related quality of life, in terms of the number of 
quality-adjusted life years (QALYs) gained by an 
intervention or service. Health-related quality of life 
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was not collected in the THIN database; hence, pub-
lished utilities for VLUs,12 previously obtained from 
the general public across the UK, using standard 
gamble methodology, were assigned to each 
patient in the model. This enabled an estimation of 
patients’ expected health status in terms of the 
number of QALYs at 6  months from the start of 
treatment with each dressing.
l Model outputs The primary measure of clinical 
effectiveness used was patients’ heath status in 
terms of the number of QALYs at 6 months. Second-
ary measures were a range of clinical outcomes, 
including the probability of healing, time to heal-
ing, and reduction in analgesic and antibiotic use 
over the study period. By assigning unit resource 
costs at 2010/11 prices13–15 to the resource utilisation 
estimates within the decision model, the 6-monthly 
health-care cost of managing patients treated with 
each dressing was estimated. 
l  cost-effectiveness analyses The cost-effective-
ness of the different dressings relative to one anoth-
er was calculated as the difference between the cost 
of alternative treatment strategies over 6  months, 
divided by the difference in the number of QALYs 
between the same alternative treatment strategies at 
6  months. Hence, the cost-effectiveness of one 
dressing relative to another was defined as the cost 
per QALY gained. If one of the dressings resulted in 
an improved outcome for less cost, it was consid-
ered to be the dominant treatment. 
l Sensitivity analyses To assess uncertainty with-
in the model, bootstrapping was undertaken to esti-
mate the distribution of expected costs, outcomes 
and cost-effectiveness ratios. This involved generat-
ing 10 000 subsets of the data from each group on 
the basis of random sampling and replacing the 
data once sampled. Use of these subsets enabled the 
construction of cost-effectiveness acceptability 
curves, showing the probability of alternative treat-
ments being cost-effective at different thresholds. In 
order to rank the superabsorbents in order of value 
for money to the NHS, the net monetary benefit of 
each was generated from the boostrapped subsets. 
Additionally, deterministic sensitivity analyses were 
performed on all the model’s inputs to identify how 
the incremental cost-effectiveness of one strategy 
over the other would change by varying the differ-
ent parameters in the model.
ranking of attributes
In a study by Vermeulen et al.,16 different attributes 
of wound dressings were scored as follows:
l Frequency of dressing change = 14
l Pain during dressing change = 7
l Wound healing time = 5
The importance of the attributes being reflected by 
the higher score. Healing was not ranked in this 
study; however, we assumed it to be as important as 
frequency of dressing change, and assigned it a value 
of 14. Additionally, reduction in analgesic use was 
used as a proxy for pain during dressing change.
Table 1. Patients’ characteristics in the dataset, at study start
   cMc    dM   f   K   S
no. of patients 99 43 99 99 99
age (years)* 74.3 71.7 74.9 70.3 74.3 
 (71.5; 77.0) (67.1; 76.3) (72.6; 77.3) (67.1; 73.4) (71.6; 77.1)
Male (%) 52% 42% 47% 47% 40%
Wound duration 3.5 6.8 6.5 9.9 19.8 
(months)*† (2.4; 4.6) (5.8; 7.8) (3.9; 9.0) (6.8; 13.0) (14.4; 25.3)
Wound  62.6 241.9 245.8 277.3 209.7 
size (cm2)*‡ (53.9; 71.4) (190.5; 293.3) (201.9; 289.8) (240.4; 314.3) (177.9; 241.6)
Mean no.  1.8 2.8 2.3 2.1 3.2 
of different  
dressings used
analgesic 35% 49% 49% 51% 46% 
use (%)§
antibiotic 100% 100% 100% 100% 100% 
use (%)
 
* results present as mean values with 95% confidence intervals in parentheses;  
† S compared with other groups, p < 0.001; ‡ cMc compared with other groups, p < 0.001;  
§ cMc compared with KM, p < 0.05
Table 2. Patient comorbidities
comorbidities (%) cMc dM f K S
Genito-urinary disorder 19% 9% 15% 9% 6%
Endocrinological/metabolic disorder 33% 30% 35% 34% 27%
cardiovascular disorder 68% 60% 73% 71% 58%
cerebrovascular disorder 5% 2% 2% 3% 4%
Peripheral vascular disease 13% 5% 12% 10% 16%
Dermatological disorder 23% 21% 27% 24% 20%
Psychiatric illness 30% 53% 36% 49% 30%
Musculoskeletal disorder 57% 56% 45% 47% 48%
neurological disorder 10% 19% 11% 16% 14%
Pulmonary disease 14% 23% 17% 20% 16%
Immunological disorder 19% 9% 24% 20% 22%
Gastrointestinal disorder 15% 9% 18% 4% 6%
cancer 14% 28% 20% 10% 14%
research
s
j o u r n a l  o f  wo u n d  c a r e   vo l  2 2 , n o  3 , M a r c h  2 0 1 3 1 1 3
The superabsorbents were ranked from 4 to 1 in 
order of decreasing value for each of these attributes 
individually. This value was then multiplied by 
the score estimated by Vermeulen et al. in order to 
value and rank the superabsorbents, according to 
their attributes.
Results
Patients in the five groups were matched by age and 
gender (Table 1), with no significant differences in 
patients’ comorbidities detected between the 
groups, using a Chi-squared test (Table 2). However, 
patients treated with S had significantly older 
wounds than patients in the other four groups. Nev-
ertheless, patients only received a mean 2–3 differ-
ent dressings before the start of their study treat-
ment, irrespective of the age of their wound 
(Table  1). Additionally, the wounds in the CMC 
group were significantly smaller than those in the 
other four groups (Table 1). 
Approximately a third of patients in all five groups 
were initially treated at the time of diagnosis with 
an antimicrobial dressing; 14–27% of patients were 
treated with a soft polymer dressing and 10–17% 
with an absorbent dressing (but not CMC). None of 
the patients received another superabsorbent before 
the start of their study treatment. Patients’ use of 
dressings before the start of their study treatment is 
summarised in Table 3.
Patient management and outcomes
Between 17% and 23% of patients never received 
compression for their VLU. Moreover, no significant 
differences were observed in the wound healing rate 
and time to healing between the five groups. How-
ever, there was a significant difference in the percent 
change in size of unhealed wounds in the CMC 
group compared with the other four groups. Wounds 
that remained unhealed in the CMC group increased 
in size by a mean 43%, whereas the unhealed wounds 
in the other groups decreased in size by 20–53% 
(p < 0.001). There were no differences in the wound 
size at baseline between those wounds that healed 
and those that remained unhealed, in each group, 
except the F group. The wounds that remained 
unhealed in the F group were larger than the wounds 
that healed. Analgesic and antibiotic use decreased 
during the study period and < 5% of patients died. 
However, there were no significant differences in 
patients health status in terms of their number of 
QALYs at 6 months (Table 4).
Logistic regression showed that the age of the 
wound was an independent predictor of non-heal-
ing (OR: 0.982 [95%CI: 0.968; 0.993]; for each 
month; p < 0.02). Additionally, analgesic use at the 
start of treatment was an independent predictor of 
non-healing (OR: 0.622 [95%CI: 0.453; 0.886]; 
p < 0.05). However, logistic regression showed that 
Table 3. dressings used before the start of the study treatments
 cMc dM f K S
first dressing at diagnosis
antimicrobials 32% 29% 32% 25% 33%
Soft polymers 27% 6% 19% 21% 14%
absorbents 10% 6% 17% 17% 14%
low adherence dressings 5% 13% 13% 13% 14%
Foams 12% 13% 10% 13% 8%
hydrogels 4% 6% 6% 0% 6%
alginates 1% 6% 1% 3% 4%
hydrocolloids 4% 6% 1% 0% 1%
other 5% 15% 1% 8% 6%
Second dressing after diagnosis
low adherence dressings 23% 7% 38% 32% 22%
antimicrobials 10% 14% 9% 32% 17%
odour absorbents 3% 21% 13% 0% 12%
Soft polymers 17% 0% 3% 7% 12%
alginates 7% 0% 13% 14% 10%
Silicone keloids 10% 36% 13% 5% 7%
absorbents 7% 0% 6% 5% 5%
hydrogels 17% 14% 3% 2% 5%
other 6% 8% 2% 3% 10%
fig 1. Percentage of patients who received an analgesic at the 
start of treatment
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patients’ age, gender, initial wound size and type of 
absorbent dressing used were not independent 
predictors of healing.
Logistic regression also showed that use of com-
pression was an independent predictor of patients 
using analgesics over the study period (OR: 2.842 
[95%CI: 1.63; 5.68]; p < 0.01), while use of antibiotics 
during the study period was also an independent pre-
dictor of patients using analgesics (OR: 3.244 [95%CI: 
1.855; 5.698]; p < 0.001). Use of analgesics was not 
affected by patient’s age, gender, initial wound size, 
wound age or absorbent dressing used. However, use 
of analgesics at the start of treatment varied accord-
ing to the compression system used (Fig 1).
Use of compression and wound age were both 
independent predictors of patients using anti-
biotics over the study period: use of compression 
(OR: 1.88 (95%CI:1.15; 3.14); p < 0.03) and wound 
age (OR: 1.021 (95%CI: 0.990; 1.039) for each 
month; p < 0.02). Use of analgesics during the 
study period was an independent predictor of 
patients using antibiotics (OR: 3.263 (95%CI: 
1.929; 5.595); p < 0.001). However, use of anti-
biotics was not affected by a patient’s age, gender, 
initial wound size or absorbent dressing used.
resource use
There were differences in resource use between the 
five groups, although they were not statistically sig-
nificance (Table  5). Patients were predominantly 
managed by practice nurses and community nurses. 
Only three patients were seen by a tissue viability 
nurse for one visit in a hospital outpatient clinic. 
Thirty-five per cent of all patients were seen by a GP 
for their VLU and 23% were referred to a physician 
in an outpatient clinic. Patients’ dressings were 
changed, on average, every 2–4 days and, over the 
6-month study period, patients received a mean 
2–3  dressings and a compression bandage at each 
dressing change.
Multiple linear regression showed that the 
6-monthly number of nurse visits was affected by:
l Use of compression, which was associated with 
8.2 more nurse visits (p < 0.001)
l Use of analgesics at the start of treatment, which 
was associated with 5.2 more nurse visits (p < 0.005)
l Patients’ age, which was associated with 1.3 fewer 
nurse visits for each 10 years of age (p < 0.05)
l Wound age, which was associated with 1.0 more 
nurse visit for each 10 months (p < 0.02)
l Wound size at the start of treatment, which was 
associated with 1.0  more nurse visit for each 
100cm2 (p < 0.05).
Health-care cost of patient management
The 6-monthly NHS cost of using each of the dress-
ings to manage a patient with a VLU is summarised 
in Table 6. The 6-monthly NHS cost of managing a 
VLU with S was £3700 per patient, which was 
15–28% lower than the cost of managing patients 
with the other three superabsorbents (Table 6). Prac-
tice and community nurse visits were the primary 
cost drivers in all groups, accounting for 67–78% of 
the 6-monthly NHS cost. Dressings accounted for 
up to a further 22% of the costs and compression 
bandages for up to a further 7%. GP visits and hos-
pital outpatient visits accounted for < 3% of the 
NHS cost of patient management.
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continued on page 118
Table 4. Patient outcomes at 6 months
 cMc  dM f K S
changed superabsorbent (%) 7% 28% 25% 8% 16%
never received compression (%) 23% 23% 17% 19% 18%
Wound healed (%) 56% 39% 45% 54% 55%
change in size of unhealed wounds (%)† 43% -22% -53% -20% -40%
Time to healing (months)* 2.6 (2.3; 3.0) 2.1 (1.6; 2.6) 3.3 (3.0; 3.6) 2.8 (2.4; 3.2) 2.9 (2.6; 3.2)
Mean size of wound that healed (cm2)* 58.0 202.0 211.9 284.8 229.9
 (30.2; 51.5) (147.5; 256.5) (124.9; 228.0) (142.8; 245.3) (133.2; 232.6)
Mean size of wound that remained 68.9 206.0 284.1 265.1 196.4
unhealed (cm2)* (34.0; 63.5) (146.3; 265.7) (189.6; 337.1) (125.1; 237.5) (93.0; 171.1)
reduction in analgesic use over study (%)‡ 22% 47% 27% 11% 31%
reduction in antibiotic use over study (%)§ 34% 19% 22% 27% 32%
no. of QalYs* 0.367 0.335 0.343 0.344 0.345
 (0.365; 0.369) (0.332; 0.338) (0.341; 0.345) (0.342; 0.346) (0.343; 0.347)
Died (%) 2% 5% 5% 1% 3%
 
* values in parenthesis represent 95% confidence intervals; 
† cMc compared with other groups, p < 0.001; ‡ DM compared with other groups, p < 0.02; § DM compared with other groups, p < 0.05
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cost-effectiveness analyses
Unhealed wounds that were treated with CMC 
became larger. Since a clinician cannot predict 
which wound will heal with any given dressing, and 
based on the evidence from this study’s data set, 
CMC cannot be recommended for the treatment of 
highly exuding chronic wounds of ≥ 3  months of 
age. Consequently, CMC was excluded from the 
cost-effectiveness analysis.
Of the other dressings, use of S resulted in a lower 
6-monthly NHS cost and more QALYs than the other 
three superabsorbents. Hence, starting treatment with 
S was found to be the dominant strategy. Starting 
treatment with F instead of DM resulted in a NHS cost 
increase of £787 and a gain of 0.01 QALYs, and start-
ing treatment with K instead of DM resulted in a NHS 
cost increase of £422 and a gain of 0.01 QALYs. Hence, 
the cost per QALY gained of using K or F instead of 
DM was £50 376 and £106 935, respectively. Hence, 
neither K nor F are cost-effective relative to DM, as the 
cost per QALY gained is greater than the National 
Institute for Health and Clinical Excellence’s (NICE) 
recommended threshold of £20 000.17
These analyses suggest that S is the preferred 
treatment followed by DM, K, F and CMC, in that 
order. Notwithstanding this, neither K nor F are 
expected to afford the NHS value for money, when 
compared with S and DM.
Sensitivity analyses
Bootstrapping was performed to identify the distri-
bution in the incremental costs and QALYs at 
6 months, for the four alternative superabsorbents 
(Fig  2), with samples from the more cost-effective 
dressings tending towards the bottom right-hand 
(dominant) quadrant.
Cost-effectiveness acceptability curves were gener-
ated from the boostrapped subsets (Fig 3). These dem-
onstrated that, at a cost-effectiveness threshold of 
£20 000 per QALY, up to 97% of a cohort is expected 
to be treated cost-effectively with S compared with 
Table 5. Mean 6-monthly amount of resource use per patient
resource cMc    dM   f   K   S
GP surgery visits* 0.6 (0.4; 0.8) 0.7 (0.4; 1.0) 0.6 (0.4; 0.8) 0.4 (0.2; 0.6) 0.5 (0.3; 0.7)
GP home visits* 0.1 (0.0; 0.2) 0.1 (0.0; 0.2) 0.2 (0.0; 0.4) 0.1 (0.0; 0.2) < 0.1 (0.0; 0.1)
Practice nurse visits* 18.1 (14.2; 22.0) 19.0 (12.8; 25.3) 14.4 (11.6; 17.2) 19.5 (14.9; 24.1) 16.0 (12.9; 19.2)
community nurse visits* 22.5 (17.6; 25.4) 38.6 (25.9; 51.3) 67.9 (54.5; 81.3) 54.1 (41.3; 66.9) 43.9 (35.3; 52.6)
hospital outpatient visits* 0.6 (0.3; 0.9) 0.7 (0.2; 1.2) 0.6 (0.4; 0.8) 0.9 (0.6; 1.3) 0.5 (0.2; 0.8)
no. of dressings* 117.0 171.4 183.6 215.3 131.9
 (94.0; 140.1) (104.8; 238.0) (140.2; 227.0) (155.9; 274.7) (92.9; 170.9)
no. of compression bandages* 50.0 57.9 117.3 96.8 83.7
 (39.2; 60.8) (31.9; 83.9) (80.3; 154.3) (72.0; 121.6) (50.7; 116.7)
laboratory tests* 0.5 (0.3; 0.7) 0.3 (0.1; 0.5) 0.3 (0.2; 0.4) 0.6 (0.3; 0.9) 0.3 (0.2; 0.4)
Diagnostic procedures* 0.1 (0.0; 0.2) 0.1 (0.0; 0.3) 0.1 (0.0; 0.2) 0.1 (0.0; 0.2) < 0.1 (0.0; 0.1)
Surgical and therapeutic procedures* < 0.1 (0.0; 0.1) < 0.1 (0.0; 0.1) < 0.1 (0.0; 0.1) < 0.1 (0.0; 0.1) <0.1 (0.0; 0.1)
Frequency of dressing change (days) 4.0 3.2 2.2 2.6 3.2
no. of dressings per change 2.5 2.9 2.2 3.1 2.2
no. of bandages per change 1.0 1.0 1.4 1.3 1.3
 
* values in parenthesis represent 95% confidence intervals
fig 2. Scatterplot of the incremental cost-effectiveness of S, K and 
f, each compared with dM at 6-months after start of treatment
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DM. However, only 30% of a cohort is expected to be 
treated cost-effectively with K compared with DM 
and only 10% is expected to be cost-effectively treated 
with F compared to DM. These analyses suggest that 
neither K or F would afford a cost-effective use of NHS 
resources when compared with S and DM.
Analysis of the net monetary benefit of each 
superabsorbent demonstrated that S affords the 
greatest value for money to the NHS, followed by 
DM, K and F, implying that S should be the pre-
ferred treatment of choice and F should be the last 
treatment of choice (Fig 4).
Deterministic sensitivity analyses were performed 
on all the model’s inputs, but only the main findings 
have been presented (Table 7). These analyses found 
the relative cost-effectiveness of S, DM, K and F to be 
sensitive to changes in healing rates, time to healing, 
number of practice nurse visits, number of commu-
nity nurse visits and number of dressings. The relative 
cost-effectiveness of the four superabsorbents was not 
sensitive to changes in any other model input.
ranking of attributes
When the score estimated by Vermeulen et al. was 
assigned to each of the superabsorbents, it was 
found that S scored the highest value followed by 
DM, K and the F (Table 8). This ranking was consist-
ent with that identified by the estimated net mone-
tary benefit of each of the superabsorbents and rein-
forces the finding that S is the preferred dressing 
and F should be the last treatment of choice. This 
may be indicative of the finding that the ability of F 
to facilitate healing may be constrained by wound 
size, whereas there was no difference in wound size 
between those wounds that did and did not heal 
with the other three superabsorbents.
Discussion
This comparative study aimed to determine the rela-
tive clinical and cost-effectiveness of using CMC, 
DM, F, K and S in the treatment of highly exuding 
chronic VLUs in the UK. Accordingly, patients in 
the THIN database who had a VLU that was 
≥ 3 months of age and who were initially managed 
with one of these dressings were compared and fol-
lowed-up for 6 months. The advantage of using the 
THIN database is that the treatment patterns and 
associated resource use observed in this study were 
based on actual clinical practice, rather than trial 
protocol-driven resource use. 
However, this naturalistic approach does have its 
limitations. Patients were not randomised to the 
treatment they received and resource use, while col-
lected prospectively, was analysed retrospectively. 
Moreover, DM was used to a greater extent to treat 
leg ulcers with an underlying cancer aetiology than 
the other superabsorbents. These patients were 
excluded from the analysis, as it was considered that 
Table 6. Mean 6-monthly nHS cost of resource use per patient 
(at 2010⁄11 prices)
resource   cMc   dM   f   K   S
GP visits 29.9 (1%) 26.2 (1%) 45.5 (1%) 24.2 (1%) 18.2 (< 1%)
Practice nurse visits 819.7 (33%) 946.4 (22%) 696.5 (14%) 916.4 (19%) 715.3 (19%)
community nurse 1023.2 1983.1 3292.4 2535.7 1958.4 
visits (42%) (46%) (64%) (53%) (53%)
outpatient visits 55.6 (2%) 73.4 (2%) 61.6 (1%) 79.3 (2%) 48.6 (1%)
Dressings 259.3 (11%) 963.6 (22%) 653.1 (13%) 534.7 (11%) 458.8 (12%)
compression 136.0 (6%) 193.4 (4%) 274.1 (5%) 290.3 (6%) 259.1 (7%) 
bandages
Drugs 53.3 (2%) 97.3 (2%) 70.8 (1%) 123.1 (3%) 79.8 (2%)
laboratory/ 6.0 (< 1%) 5.3 (<  1%) 3.6 (< 1%) 3.3 (< 1%) 1.0 (< 1%) 
diagnostic tests
Surgical/therapeutic 54.0 (2%) 0.0 (0%) 16.0 (< 1%) 241.0 (5%) 90.0 (2%) 
procedures
consumables 15.8 (1%) 58.0 (1%) 14.0 (< 1%) 20.1 (< 1%) 45.1 (1%)
Total 2452.8 4346.7 5127.6 4768.1 3674.3
 
Percentage of total cost is given in parentheses
Table 7. Sensitivity analyses showing the range in the mean 
6-monthly nHS cost, and number of QalYs per patient, 
associated with varying different parameters in the model
Scenario   S   K   f   dM
healing rate ranges £7983–£2661 £10 326–£3442 £9333–£3111 £6840–2280 
from 0.25 to 0.75 (0.159–0.477) (0.159–0.476) (0.189 -0.566) (0.213–0.639)
Time to healing ranges £7348–£2449 £9538–£3179 £10 266–£3422 £4346–4346 
from 50% below to 50% (0.533–0.283) (0.530–0.282) (0.499–0.291) (0.467–0.291)
above base case values
no. of practice nurse £3317–£4032 £4310–£5226 £4779–£5476 £3874–£4820 
visits ranges from 50% (no effect) (no effect) (no effect) (no effect) 
below to 50% above  
base case values
no. of community nurse £2695–£4654 £3500–£6036 £3481–£6774 £3355–£5338 
visits ranges from 50% (no effect) (no effect) (no effect) (no effect) 
below to 50% above  
base case values
no. of dressings ranges  £3445–£3904 £4501–£5035 £4801–£5454 £3865–£4829 
from 50% below to 50% (no effect) (no effect) (no effect) (no effect) 
above base case values
no. of compression £3545–£3804 £4623–£4913 £4991–£5265 £4250–£4443 
bandages ranges from (no effect) (no effect) (no effect) (no effect) 
50% below to 50% 
above base case values 
 
range in mean 6-monthly number of QalYs per patient given in parentheses
research
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the outcomes of managing these wounds would be 
different to that of routine management of venous 
leg ulcers and not be consistent with the other 
wounds analysed in this study.
Consequently, 439 matched patients were includ-
ed in the analysis. It is notoriously difficult to power 
health economic studies where the metric is use of 
different resources or a range of clinical outcomes, 
which are unknown at the outset. However, power 
calculations showed that the sample size was suffi-
ciently large to detect any significant differences in 
nurse visits with 95% power and a type  I (alpha) 
error of 0.05 between the groups, had they occurred. 
For patients to have been included in the data set 
they had to have received CMC, DM, F, K or S for 
their VLU, and be matched on the basis of their age, 
gender, the same general practice and date of diag-
nosis of their VLU. However, the size of the VLUs 
treated with CMC were significantly smaller than 
those in the other four groups. Additionally, wounds 
treated with S were significantly older than those in 
the other four groups. Nevertheless, regression anal-
ysis showed that healing was not affected by the 
wound size at the start of treatment. A wound’s age 
at the start of treatment was an independent predic-
tor of non-healing; however, due to the nature of 
the data set, it was not possible to assess whether 
the healing rate associated with S would have been 
higher if used to treat wounds of 6 months rather 
than 20 months of age. 
The findings raise the question as to why S was 
reserved for wounds that were significantly older 
than the wounds treated with the other dressings. 
However, irrespective of a wound’s age, the patients 
in the data set only received 2–3 different dressings 
before the start of the study treatment and, interest-
ingly, none of the patients received another super-
absorbent before the start of their study treatment. 
The patients in the data set were managed by a 
practice or community nurse, who saw them on 
average every 2–4 days. Moreover, only 35% of all 
patients were seen by a GP for their VLU and only 
23% were referred to a hospital specialist. Addition-
ally, only three patients were seen by a tissue viabil-
ity nurse for one appointment. This could be a 
reflection of how most patients with a VLU are now 
being managed in the community in the UK. The 
VLU healing rates found in this study, which reflect 
‘real-world’ practice, are consistent with those 
reported in other studies (55–65% at 12 weeks).18,19
Our study does not address the question of who 
should be diagnosing and managing VLUs, how 
should it be done or the more complex question of 
integrated care pathways. However, in the NHS’ 
Venous Leg Ulcer and Wound Healing Implementa-
tion Pack, a healing rate below 70% at 6 months and 
an infection rate of > 0% would be deemed a breach 
of performance.20 Consequently, implementation of 
care pathways, improving clinician education in pri-
mary care on the management of VLUs has the 
potential to increase the use of cost-effective inter-
ventions, improve outcomes and release health-care 
resources for alternative use within the system.
limitations
This study has a number of other limitations. The 
results were censored at 6 months and excluded the 
costs and consequences of managing patients 
beyond this period. The THIN database may have 
under-recorded use of some health-care resources 
outside the GP’s surgery, such as home visits made 
by GPs, home visits made by nurses, outpatient 
Table 8. ranking of attributes
ranking of attributes based on this study’s findings
 dM f K S
healing 1 2 3 4
Time to healing 4 1 3 2
reduction in analgesic use 4 2 1 3
Frequency of dressing change 4 1 2 4
Value of attributes using the ranking value estimated by Vermeulen et al.
healing 14 28 42 56
Time to healing 20 5 15 10
reduction in analgesic use 28 14 7 21
Frequency of dressing change 56 14 28 56
Total value of attributes 118 61 92 143
fig 3. cost-effectiveness acceptability curves
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visits, and attendances at accident and emergency 
departments. The analysis only considered the cost 
of NHS resource use for the ‘average patient’ and no 
attempt was made to stratify resource use and costs 
according to gender, comorbidities, suitability of 
patients for different treatments and other disease-
related factors. Also excluded were the costs incurred 
by patients and indirect costs incurred by society as 
a result of patients taking time off work. However, 
the patients’ mean age was > 65 years, so it is unlike-
ly that many were in employment.
There are many outcomes that could be used to 
assess the effect of an intervention on a wound, 
including wound healing, time to healing, wound 
size reduction, granulation, exudate reduction and 
epithelialisation. However, the records in the THIN 
database did not include all of this information for 
all patients. In particular, the reasons why unhealed 
wounds in the CMC group increased in size. This 
might be due to maceration, but the findings warrant 
investigation in a prospective study. Notwithstand-
ing these limitations, S appears to be clinically more 
effective than the other superabsorbents in treating 
highly exuding chronic VLUs, as judged by the 
attributes that could be quantified. Furthermore, use 
of S leads to lower NHS costs. Over the 6 months fol-
lowing the start of treatment with S, the NHS cost of 
VLU management was estimated to be ~£3800, 
which was 15–28% less than the cost of managing 
patients with the other superabsorbents evaluated in 
this study. Unsurprisingly, the overall 6-monthly cost 
of patient management and the patterns of resource 
use were concordant with our previous health eco-
nomic studies on VLU management.11,12,21
This evaluation provided an estimate of the clini-
cal outcomes, resource implications and associated 
costs attributable to managing VLUs with five differ-
ent dressings. While the study results are compel-
ling, the analyses of clinical outcomes were based 
on clinicians entries into their patients’ records, and 
inevitably subject to a certain amount of impreci-
sion and lack of detail. Moreover, the computerised 
information in the THIN database is collected by 
GPs for clinical care purposes and not for research. 
Prescriptions issued by GPs and practice nurses are 
recorded in the database, but it does not specify 
whether the prescriptions were dispensed or patient 
compliance with the product. Consequently, this 
study’s findings should provide a framework for ran-
domised controlled trials comparing the use of 
alternative superabsorbents in the management of 
VLUs to prospectively measure wound size, infec-
tion, healing and other clinical outcome measures, 
health-related quality of life in combination with 
cost-effectiveness metrics. Moreover, given that 
most patients with a VLU are managed in the com-
munity, it was legitimate from a health economics 
point of view to perform this study from the com-
munity perspective using the THIN database.
Conclusion
Within the limitations of the data set, S affords the 
NHS a cost-effective treatment for managing highly 
exuding chronic VLUs of ≥ 3 months of age, com-
pared with DM, F, K and CMC. n
fig 4. net monetary benefit of the four superabsorbents
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